市場調查報告書
商品編碼
964946

食慾抑制劑的全球市場:成長,趨勢,預測(2020年∼2025年)

Anorexiants Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 121 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

食慾抑制劑的市場規模在預測期間內預計將以3.9%的年複合成長率成長。市場增長的主要因素是久坐的生活方式增加,缺乏體育鍛煉以及不良的飲食習慣導致體重增加。根據世界衛生組織的一份報告,2017年,全球約有6.5億成年人和4100萬5歲以下的兒童肥胖。預計肥胖率在預測期內將迅速增加。因此,控制其他健康並發症和肥胖相關疾病的全球醫療保健費用激增有望推動市場。

這份報告提供食慾抑制劑的世界市場調查,提供市場概要,市場成長要素及阻礙因素分析,市場機會,給藥途徑·通路·各地區的市場規模的變化與預測,競爭情形,主要企業的簡介等系統性資訊。

目錄

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 市場推動因素
    • 由於現代久坐不動的生活方式,全球肥胖病例增加
    • 已開發國家的意識和可支配所得的提高
  • 市場阻礙因素
    • 新興國家品牌產品的高成本
    • 與藥物治療有關的嚴重不良事件,包括發作,自殺未遂甚至死亡
    • 傳統的瑜伽和藥草產品的採用
  • 波特的五力分析

第5章 市場區隔

  • 各給藥途徑
    • 皮下
    • 口服
  • 各銷售管道
    • 線上藥局
    • 零售藥局
    • 醫院藥局
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東和非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Novo Nordisk Inc.
    • Lannett Co. Inc.
    • Currax Pharmaceuticals LLC
    • F. Hoffmann-La Roche AG
    • Pfizer Inc.
    • Vivus Inc.
    • Hi-Tech Pharmaceuticals
    • KVK Tech Inc.
    • Elite Pharmaceuticals Inc.
    • Productos Medix SA de CV

第7章 市場機會及趨勢

目錄
Product Code: 68552

The anorexiants market studied is anticipated to register a CAGR of 3.9% during the forecast period. The major factors attributing to the growth of the market are a rise in the sedentary lifestyle, physical inactivity, and poor dietary habits resultant weight gain. According to the World Health Organization report, in 2017, about 650 million adults and 41 million children aged under 5 years were obese worldwide. Also, the report states that the obesity rate is expected to grow rapidly during the forecast period. Thus, a steep rise in global healthcare expenditure to control other health complications and obesity-related diseases is expected to drive the market.

Key Market Trends

Oral Anorexiants Segment is Expected to Hold the Major Market Share in the Anorexiants Market

Oral Anorexiants dominated the market in past few years, and it is expected to do so over the forecast period. The higher demand for these products can be due to the increased preference of the patients owing to their non-invasive treatment. Also, their easier administration without the need for skilled healthcare professionals increased the adoption rate among the patients and physicians. Furthermore, higher availability of products in tablets and capsules, as well as increased awareness by key players are expected to lead to the growth of the segment.

North America Dominates the Market and Expected to do Same in the Forecast Period.

North America has been the primary market for anorexiants market owing to the rise in the number of complications associated with obesity in the region. Major chronic diseases prevailing in the region include diabetes, coronary heart disease, and certain types of cancer.

According to the factsheet published by the Centers for Disease Control and Prevention (CDC), the prevalence of obesity in 2016 was 39.8%, affecting about 93.3 million US adults which increased to 41.2 % in 2017. Also, as per the Organization for Economic Co-operation and Development report in 2020, the United States is estimated to spend the highest Health Expenditure on Obesity and Related Conditions across the globe during 2020-2050.

Increasing obesity cases in the region can be due to a sedentary lifestyle and unhealthy dietary habits. Furthermore, overweight gain affects an individual's psychological, behavioral, and psychiatric characteristics. Additionally, the presence of key players, a huge target population with disposable income in the United States is anticipated to drive the market growth over the forecast period.

Competitive Landscape

The Anorexiants Market is moderately competitive and consists of several major players. Few of the major players are implementing various strategies like increased investments in R&D and mergers & acquisitions. For instance, in September 2019, Currax Pharmaceuticals LLC, acquired Nalpropion Pharmaceuticals, a biopharmaceutical company focused on the treatment of weight loss. With the acquisition deal, Currax has owned the world-wide rights to Contrave, the number one prescription weight-loss brand medication in the United States and Europe. Strategic alliances such as these are expected to boost the sales globally. Some of the companies currently dominating the market are Novo Nordisk Inc., Lannett Co. Inc., Currax Pharmaceuticals LLC, F. Hoffmann-La Roche AG, and Pfizer Inc.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 The Rise in Global Prevalence of Cases of Obesity due to Modern Sedentary Lifestyles
    • 4.2.2 Rise in Awareness and Disposable Income in Developed Economies
  • 4.3 Market Restraints
    • 4.3.1 Highly Cost of Branded Products in Emerging Countries
    • 4.3.2 Severe Adverse Associated with Medication Including Seizures, Suicidal Attempts and Even Death
    • 4.3.3 Adoption of Traditional Yoga and Herbal Products
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Route of Administration
    • 5.1.1 Subcutaneous Anorexiants
    • 5.1.2 Oral Anorexiants
  • 5.2 Distribution Channel
    • 5.2.1 Online Pharmacy
    • 5.2.2 Retail Pharmacy
    • 5.2.3 Hospital Pharmacy
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Novo Nordisk Inc.
    • 6.1.2 Lannett Co. Inc.
    • 6.1.3 Currax Pharmaceuticals LLC
    • 6.1.4 F. Hoffmann-La Roche AG
    • 6.1.5 Pfizer Inc.
    • 6.1.6 Vivus Inc.
    • 6.1.7 Hi-Tech Pharmaceuticals
    • 6.1.8 KVK Tech Inc.
    • 6.1.9 Elite Pharmaceuticals Inc.
    • 6.1.10 Productos Medix SA de CV

7 MARKET OPPORTUNITIES AND FUTURE TRENDS